Cervical Cancer Screening Three-Year Interval Risks Weighed In NEJM Study
This article was originally published in The Gray Sheet
Triennial cervical cancer screening of women aged 30-64 who have had three previous negative Pap tests is associated with only slight "excess risk," compared with annual screening for three years, according to a study in the Oct. 16 New England Journal of Medicine
You may also be interested in...
Revised cervical cancer screening guidelines from the American College of Obstetricians & Gynecologists could facilitate adoption of Digene's recently approved DNAwithPap test for primary screening
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.